Isolated Cranial Mononeuropathy: An Unusual Initial Presentation and Disease Progression of Metastatic Carcinoma of the Breast by Lim, Ming Y. et al.
Isolated Cranial Mononeuropathy: An Unusual
Initial Presentation and Disease Progression
of Metastatic Carcinoma of the Breast
Case Report
A previously healthy 46-year-old woman presented in April 2010
with a 1-month history of right facial paresthesia with pain over the
maxillary region. She began receiving carbamazepine for presumed
trigeminal neuralgia and experienced some improvement of symp-
toms. Her neurologic symptoms persisted and she underwent a brain
magnetic resonance imaging (MRI) scan that revealed a 2.2  1.3 cm
mass within Meckel’s cave that extended along V2 and V3 branches of
the trigeminal nerve; this was concerning for perineural spread of
tumor from a nasopharyngeal or salivary gland tumor.
A sinonasal endoscopy was performed and was essentially nor-
mal. Additional imaging with a dedicated cranial nerve brain MRI
demonstrated the previously identified mass in Meckel’s cave with
extension of abnormal enhancement and thickening involving the
cisternal portion of the trigeminal nerve and along V2 and V3 (Figs 1A
and 1B, arrows). Multiple lytic lesions at the posterior vertex of the
skull, the clivus, the right lateral aspect of C1, the dens, and the body of
C2 were also identified. A positron emission tomography with con-
current computed tomography (PET/CT) revealed a 3.5  2.1 cm
intensely 18F-fluorodeoxyglucose (FDG) –avid left medial breast
mass, and two moderately FDG-avid masses measuring 2.7  2.0
cm and 1.2  0.9 cm, in the upper outer quadrant of the right
breast. There were also widespread lytic lesions in the thoracic
osseous structures, in addition to the known lytic lesions in the
skull base. Taking all this together, metastatic breast cancer was the
presumed diagnosis.
The patient denied any nipple discharge, breast pain, mass, infec-
tion, or trauma. Her most recent mammogram a year before was
reportedly normal. Her medical history was only significant for re-
moval of a dermoid ovarian cyst 10 years before. She reached men-
arche at age 12 years and had been prescribed the oral contraceptive
pill for 10 years. Her first child was born when the patient was age 38
years, and she reached menopause at age 44 years. She did not require
hormone replacement therapy. Family history was significant for lung
cancer and bladder cancer in two uncles, with no family history of
breast or ovarian cancer. Her BRCA mutation status is unknown.
Physical examination was significant for reduced sensation to
touch over the right maxillary facial region, with no other cranial nerve
abnormalities. The rest of the neurologic examination was normal.
Breast examination revealed a mobile, nontender, 3 cm mass in the
right upper outer quadrant and an irregular 2  3 cm mass in the left
upper inner quadrant. A diagnostic mammogram demonstrated a
spiculated mass with architectural distortion and microcalcifications
measuring 8.0  5.8  7.4 cm in the left upper inner quadrant and a
macrolobular mass within the right upper outer quadrant. Breast
ultrasound revealed a 2.8  2.1  1.7 cm spiculated, hypoechoic mass
in the left breast and a 3.4  2.1  1.5 cm macrolobular, hypoechoic
mass in the right upper outer breast.
Ultrasound-guided core biopsy of the left breast mass revealed a
grade 2 (Nottingham), estrogen receptor (ER) –positive (90%, strong
intensity), progesterone receptor (PR) –negative, and human epider-
mal growth factor receptor 2 (HER2)/neu –negative (1 via immu-
nochemistry [IHC]) infiltrating ductal carcinoma (Fig 2A,
hematoxylin and eosin staining, 400 magnification). Interestingly,
ultrasound-guided core biopsy of the right breast mass revealed a
morphologically distinct, ER-positive (95%, strong intensity), PR-
positive (90%, strong intensity), and HER2/neu-negative (0 via IHC)
infiltrating ductal carcinoma, signet ring cell variant with abundant
intracytoplasmic mucin and eccentrically placed nuclei (Fig 2B,
hematoxylin and eosin staining, 400 magnification). Fine-needle
aspiration of the right ilium lesion revealed metastatic breast adeno-
carcinoma similar to that present in the left breast primary cancer,
with a similar immunophenotypic receptor profile (positive for ER
[93%], negative for PR, and HER2/neu was not overexpressed).
Signet ring cells were not identified in the bone metastasis.
With involvement of the trigeminal nerve, lumbar puncture was
performed. CSF analysis revealed a cell count of 1/L, protein concen-
tration of 75 mg/dL, and glucose concentration of 74 mg/dL; cytology
did not demonstrate any malignant cells present. These findings were
not consistent with a diagnosis of leptomeningeal carcinomatosis.
Neither CA-15.3/27.29 nor CA-125 was tested on the CSF. Given the
patient’s persistent neurologic symptoms, she received palliative radi-
ation to the base of the skull via opposed lateral beams, with 3 Gy over
10 fractions for a total dose of 30 Gy over a 2-week period. Given the
endocrine-sensitive and HER2/neu-negative nature of her tumor and
her postmenopausal status on the basis of follicle stimulating hor-
mone, luteinizing hormone, and estradiol laboratory parameters, she
was prescribed an aromatase inhibitor, letrozole. For her bone metas-
tases, monthly zoledronic acid infusions were initiated. She also con-
tinued to receive narcotic therapy for pain, gabapentin for neuralgia,
and corticosteroids and antiemetic therapy for supportive care.
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By week 8 after initiation of radiation and systemic therapies, the
patient’s pain control had improved significantly, so that she was able
to self-discontinue narcotics and continued to receive gabapentin. At
12 weeks, she underwent restaging studies. PET/CT imaging revealed
a stable appearance of the left breast mass and decreased size of the
right breast mass, with mixed responses of her widespread osseous
metastatic disease. She continued to receive letrozole and monthly
zoledronic acid infusion.
In January 2011, repeat PET/CT imaging revealed an increase in
size of the left breast mass and left axillary lymph node. The patient was
switched to second-line endocrine therapy with fulvestrant (Faslodex;
AstraZeneca, Wilmington, DE). Repeat imaging in May 2011 contin-
ued to show disease progression, and she was switched to exemestane
(Aromasin; Pfizer, New York, NY). In September 2011, she developed
diplopia and was found to have a right sixth cranial nerve palsy. Given
that repeat lumbar puncture was negative for leptomeningeal carcino-
matosis, it was thought that the sixth cranial nerve palsy was a result of
compression by bony metastasis in the right clivus within the skull. She
was transitioned to tamoxifen. Repeat imaging in January 2012 dem-
onstrated disease progression with increased liver metastases, and she
was switched from endocrine therapy to chemotherapy with capecit-
abine. In July 2012, she presented with new left maxillary paresthesia.
Repeat brain MRI confirmed progression of disease with worsening
involvement of the right trigeminal nerve and new involvement of the
V2 and V3 branches of the left trigeminal nerve.
Because the patient was symptomatic neurologically, the decision
was made to reirradiate with an additional 2 Gy over seven fractions
for a total dose of 14 Gy (with opposed lateral beams), which she
tolerated well. This low dose was given to limit the cumulative dose to
the underlying optic apparatus. The patient has recently been transi-
tioned to single-agent carboplatin chemotherapy, with reimaging
scans scheduled at standard intervals.
Discussion
Although uncommon, cranial mononeuropathy has been re-
ported in the literature as a manifestation of metastatic neoplasms. In
the majority of cases, the neuropathy is caused by either diffuse me-
tastasis to the leptomeninges1 or dura mater,2 or direct intracranial
extension from invasive head and neck tumors. Solitary metastasis to
an isolated cranial nerve from a distant primary tumor is rare but has
been reported, particularly for trigeminal neuropathy in lung,3 lym-
phoma,4 colorectal cancer,5 and breast cancer.6-9
Similar to the reported cases, our patient presented initially with
right trigeminal mononeuropathy, with improvement in symptoms
after local and systemic therapy. She subsequently developed right
abducens mononeuropathy and then left trigeminal mononeuropa-
thy, indicating disease progression. Interestingly, throughout her clin-
ical disease, she had no evidence of leptomeningeal carcinomatosis,
which one would have expected, given the involvement of multiple
cranial nerves. Although a paraneoplastic neuropathy could account
for the multiple cranial nerve involvement,10 simultaneous neuropa-
thies are usually reported and are not consistent with our patient’s
presentation, given initial brain MRI findings. Moreover, our patient
had sequential involvement of multiple cranial nerves with disease
progression, which, to our knowledge, has not been reported previously.
Another unique feature of our patient case is the presence of
signet ring cells in the right breast biopsy. Signet ring cell carcinoma
(SRCC) of the breast is uncommon, with an incidence of between 2%
and 4.5% of total breast cancers.11,12 It is classified as a mucinous
carcinoma and is defined by more than 20% of the malignant cells
appearing as the signet ring form of tumor. On histology, metastatic
gastric SRCC can be difficult to delineate from primary SRCC of the
breast. It is important to differentiate the two because of their differ-
ence in prognosis. In our patient, the clinical presentation, the location
of primary tumor(s) in the breast, and IHC stains that stained strongly
for ER all confirmed a primary breast SRCC.
The prognosis of SRCC of the breast is unknown because of its
rarity, but the presence of signet ring cells is believed to be a poor
prognostic factor. A study by Frost et al13 found that the presence of
10% or more signet ring cells represents a poor individual prognostic
factor in stage I infiltrating lobular carcinomas. The pure form of
SRCC of the breast is also thought to be more aggressive than muci-
nous, ductal, or lobular invasive carcinoma; in 24 patients with SRCC,
60% survived less than 7 years.11 Because we were unable to biopsy the
cranial lesions, we can only speculate whether having features of SRCC
of the breast could have accounted for this unusual presentation, with
isolated metastasis to multiple cranial nerves.
In summary, we report the case of a patient with right facial
paresthesia as the first clinical manifestation of metastatic breast can-
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disease as part of the differential diagnosis for patients presenting with
trigeminal neuropathy.
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